Yasmin H Karimi, MD
Clinical Assistant Professor of Internal Medicine
[email protected]

Available to mentor
Yasmin H Karimi, MD
Clinical Assistant Professor
  • Center Memberships
  • Recent Publications
    • Center Memberships
    • Center Member
      Institute for Healthcare Policy and Innovation
    Recent Publications See All Publications
    • Presentation
      Emerging treatments in classical Hodgkin lymphoma
      Karimi Y. 2024 Sep 28;
    • Proceeding / Abstract / Poster
      ABCL-191 Extended Follow-Up Beyond 2.5 Years Demonstrates Long-Term Efficacy in Complete Responders Following Epcoritamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)
      Karimi YH, Thieblemont C, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, Jurczak W, Linton KM, Hutchings M, Phillips T, Farooq U, Kim WS, Dinh MH, Ghosh J, Pallai R, Wielgos-Bonvallet M, Eskelund C, Lugtenburg PJ, Vose JM. Clinical Lymphoma Myeloma & Leukemia, 2024 Sep; 24: s461 - s462. DOI:10.1016/s2152-2650(24)01495-2
    • Proceeding / Abstract / Poster
      ABCL-275 Epcoritamab + GemOx Induces Deep Durable Responses in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Updated Results From EPCORE NHL-2
      Cordoba R, Jørgensen J, Belada D, Costello R, Trněný M, Vitolo U, Belada D, Karimi YH, Sureda A, André M, Wahlin BE, Lugtenburg PJ, Jiang T, Abbas A, Song Y, Risum M, Brody JD. Clinical Lymphoma Myeloma & Leukemia, 2024 Sep; 24: s468 - s469. DOI:10.1016/s2152-2650(24)01509-x
    • Proceeding / Abstract / Poster
      ABCL-616 Incidence, Characteristics and Outcomes in Relapsed and Refractory CD20+ PTLD: An Institutional Retrospective Cohort Study
      El-amir Z, McLane M, Kaminski M, Phillips T, Wilcox R, Sano D, Karimi Y, Carty S. Clinical Lymphoma Myeloma & Leukemia, 2024 Sep; 24: s486 DOI:10.1016/s2152-2650(24)01542-8
    • Proceeding / Abstract / Poster
      Epcoritamab + R-DHAX/C Induces Deep, Durable Responses in Transplant-Eligible Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL), Including High-Risk Disease
      Abrisqueta P, Falchi L, Nijland M, de Vos S, Offner F, Rana A, Archer K, Song Y, Osei-Bonsu K, Karimi Y, Cordoba R. Clinical Lymphoma Myeloma & Leukemia, 2024 Sep; 24: s214 DOI:10.1016/s2152-2650(24)00802-4
    • Journal Article
      High-Grade B-Cell Lymphoma, Not Otherwise Specified: CNS Involvement and Outcomes in a Multi-Institutional Series.
      Epperla N, Zayac AS, Landsburg DJ, Bock AM, Nowakowski GS, Ayers EC, Girton MR, Hu M, Beckman AK, Li S, Medeiros LJ, Chang JE, Kurt H, Sandoval-Sus J, Ansari-Lari MA, Kothari SK, Kress A, Xu ML, Torka P, Sundaram S, Smith SD, Naresh KN, Karimi YH, Bond DA, Evens AM, Naik SG, Kamdar M, Haverkos BM, Karmali R, Farooq U, Vose JM, Rubinstein PG, Chaudhry A, Olszewski AJ. Blood Adv, 2024 Aug 27; DOI:10.1182/bloodadvances.2024013791
      PMID: 39189932
    • Journal Article
      Exploring Adolescent and Young Adult Cancer Survivors' Experience with Cancer Treatment-Related Symptoms: A Qualitative Analysis of Semi-Structured Interviews.
      Knoerl R, Grandinetti K, Smener L, Doll E, Fecher LA, Henry NL, Karimi Y, Pettit K, Schuetze S, Walling E, Zhang A, Barton D. J Adolesc Young Adult Oncol, 2024 Aug; 13 (4): 665 - 673. DOI:10.1089/jayao.2024.0053
      PMID: 38634665
    • Proceeding / Abstract / Poster
      Abstract PO-003: Peripheral blood and tumor tissue biomarkers associated with epcoritamab response in patients with relapsed or refractory diffuse large B-cell lymphoma: Data from the dose-expansion cohort of the phase 1/2 EPCORE NHL-1 trial (NCT03625037)
      Wielgos-Bonvallet M, Zhang J, Si H, Karagoz K, Acar M, Karimi Y, Ghesquieres H, Clausen MR, Altıntaş I, Wang B, Assaily W, Loya M, Masters G, Muthuswamy A, Higgs B, Sacchi M, Ahmadi T, Fereshteh M, Szafer-Glusman E, Soong D, Jure-Kunkel M, Steele AJ. Blood Cancer Discovery, 2024 Jun 19; 5 (3_Supplement): po-003-po-003 DOI:10.1158/2643-3249.lymphoma24-po-003